Information Provided By: 
Fly News Breaks for November 5, 2019
ZBH
Nov 5, 2019 | 18:07 EDT
Piper Jaffray analyst Matt O'Brien raised his price target on Zimmer Biomet to $140 after its Q3 beat on revenue and earnings. The analyst says the higher Knee and SET sales drove the 3.9% ex-FX revenue growth, even though the quarter had one more billing day. O'Brien remains positive on Zimmer's progress on improving the performance of the business, but keeps his Neutral rating with other names trading at more attractive valuation levels.
News For ZBH From the Last 2 Days
There are no results for your query ZBH
